STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more

Biogen's experimental Alzheimer's drug diranersen showed slowed cognitive decline in a mid-stage trial, prompting a potential Phase 3 trial. A study highlighted potential frailty risks in older adults using Eli Lilly's Zepbound and Novo Nordisk's Wegovy, urging closer monitoring for seniors.